Atara Biotherapeutics (ATRA) Cash & Equivalents (2022 - 2025)
Historic Cash & Equivalents for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $5.7 million.
- Atara Biotherapeutics' Cash & Equivalents fell 8763.91% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 8763.91%. This contributed to the annual value of $25.0 million for FY2024, which is 313.84% down from last year.
- According to the latest figures from Q3 2025, Atara Biotherapeutics' Cash & Equivalents is $5.7 million, which was down 8763.91% from $16.9 million recorded in Q2 2025.
- Atara Biotherapeutics' Cash & Equivalents' 5-year high stood at $101.7 million during Q1 2022, with a 5-year trough of $5.7 million in Q3 2025.
- Moreover, its 4-year median value for Cash & Equivalents was $45.9 million (2023), whereas its average is $46.0 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 49.61% in 2023, then crashed by 8763.91% in 2025.
- Atara Biotherapeutics' Cash & Equivalents (Quarter) stood at $92.9 million in 2022, then plummeted by 72.2% to $25.8 million in 2023, then dropped by 3.14% to $25.0 million in 2024, then tumbled by 77.06% to $5.7 million in 2025.
- Its Cash & Equivalents was $5.7 million in Q3 2025, compared to $16.9 million in Q2 2025 and $13.8 million in Q1 2025.